神州细胞：SCTB39G获得药物临床试验批准

Core Viewpoint - The company Shenzhou Cell has received approval from the National Medical Products Administration for clinical trials of its self-developed product SCTB39G injection in patients with advanced solid tumors [1] Group 1: Product Development - SCTB39G is a multi-target immune therapy trispecific antibody injection [1] - The clinical trial will focus on the efficacy of SCTB39G as a monotherapy in late-stage solid tumor patients [1] Group 2: Regulatory Approval - The approval includes a "Drug Clinical Trial Approval Notification" which allows the company to proceed with the clinical trials [1] - The timeline and outcomes of the clinical trials, reviews, and approvals are subject to unpredictability and uncertainty [1]